Logo image of NH

NANTHEALTH INC (NH) Stock Fundamental Analysis

NASDAQ:NH - Nasdaq - US6301043054 - Common Stock - Currency: USD

1.35  -1.18 (-46.64%)

After market: 1.3 -0.05 (-3.7%)

Fundamental Rating

0

Overall NH gets a fundamental rating of 0 out of 10. We evaluated NH against 35 industry peers in the Health Care Technology industry. NH may be in some trouble as it scores bad on both profitability and health. NH has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year NH has reported negative net income.
NH had a negative operating cash flow in the past year.
NH had negative earnings in each of the past 5 years.
In the past 5 years NH always reported negative operating cash flow.
NH Yearly Net Income VS EBIT VS OCF VS FCFNH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

The profitability ratios for NH are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NH Yearly ROA, ROE, ROICNH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K

1.3 Margins

With a Gross Margin value of 58.50%, NH perfoms like the industry average, outperforming 56.82% of the companies in the same industry.
In the last couple of years the Gross Margin of NH has grown nicely.
NH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.5%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.62%
GM growth 5Y1.8%
NH Yearly Profit, Operating, Gross MarginsNH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 50 -50 -100 -150 -200

0

2. Health

2.1 Basic Checks

NH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NH has about the same amount of shares outstanding.
NH has a worse debt/assets ratio than last year.
NH Yearly Shares OutstandingNH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
NH Yearly Total Debt VS Total AssetsNH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

NH has an Altman-Z score of -10.03. This is a bad value and indicates that NH is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10.03, NH is doing worse than 79.55% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -10.03
ROIC/WACCN/A
WACC2.11%
NH Yearly LT Debt VS Equity VS FCFNH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 0.64 indicates that NH may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.64, NH is doing worse than 81.82% of the companies in the same industry.
A Quick Ratio of 0.64 indicates that NH may have some problems paying its short term obligations.
NH's Quick ratio of 0.64 is on the low side compared to the rest of the industry. NH is outperformed by 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.64
Quick Ratio 0.64
NH Yearly Current Assets VS Current LiabilitesNH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

0

3. Growth

3.1 Past

NH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -240.38%.
The Revenue has been growing slightly by 7.68% in the past year.
NH shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.02% yearly.
EPS 1Y (TTM)-240.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.27%
Revenue 1Y (TTM)7.68%
Revenue growth 3Y-4.71%
Revenue growth 5Y-5.02%
Sales Q2Q%4.13%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NH Yearly Revenue VS EstimatesNH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
NH Yearly EPS VS EstimatesNH Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 -2 -4 -6 -8 -10

0

4. Valuation

4.1 Price/Earnings Ratio

NH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NH Price Earnings VS Forward Price EarningsNH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NH Per share dataNH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for NH!.
Industry RankSector Rank
Dividend Yield N/A

NANTHEALTH INC

NASDAQ:NH (5/23/2023, 8:00:01 PM)

After market: 1.3 -0.05 (-3.7%)

1.35

-1.18 (-46.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)05-10 2023-05-10
Earnings (Next)08-02 2023-08-02
Inst Owners0%
Inst Owner Change0%
Ins Owners206.62%
Ins Owner Change0%
Market Cap10.40M
Analysts84.44
Price Target61.2 (4433.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.15
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-8.32
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-4.45
FCFYN/A
OCF(TTM)-3.61
OCFYN/A
SpS8.79
BVpS-30.72
TBVpS-47.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.5%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.62%
GM growth 5Y1.8%
F-Score3
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.75%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.64
Quick Ratio 0.64
Altman-Z -10.03
F-Score3
WACC2.11%
ROIC/WACCN/A
Cap/Depr(3y)35.53%
Cap/Depr(5y)34.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-240.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.27%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.68%
Revenue growth 3Y-4.71%
Revenue growth 5Y-5.02%
Sales Q2Q%4.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.75%
OCF growth 3YN/A
OCF growth 5YN/A